January 7, 2018 04:21 PM ESTUpdated January 7, 08:52 PM

Developing a Sanofi cast-off, Impact Biomedicines now subject of $7B Celgene acquisition deal

A startup developing the once-discarded fedratinib, a drug cast off from Sanofi due to safety concerns back in 2013, is now the subject of a …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

De­vel­op­ing a Sanofi cast-off, Im­pact Bio­med­i­cines now sub­ject of $7B Cel­gene ac­qui­si­tion deal